{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:04:57Z","timestamp":1778875497443,"version":"3.51.4"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Hemangioblastomas of the central nervous system are a prominent feature of von Hippel-Lindau-disease (vHL). Hemangioblastomas are known to secrete vascular endothelial growth factor (VEGF), suggesting a potential role of VEGF as a biomarker for tumor growth.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Plasma VEGF samples from 24 patients with von Hippel-Lindau disease were analyzed by solid-phase proximity ligation assay (PLA). Levels were monitored over time together with numeric and volumetric CNS tumor burden, and compared to plasma VEGF levels in healthy controls.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The mean yearly progression in tumor volume was 65.5%. Yearly risk of developing one or several new CNS tumor(s) was 50%. No significant correlation between tumor burden and levels of VEGF was seen. VEGF levels in patients (31.55\u201392.04; mean 55.83, median 56.41) as measured by immunodetection in a solid-phase PLA did not differ significantly from controls (37.38\u2013104.56; mean 58.89, median 54.12) (p = 0,266).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The increase in total CNS tumor volume in vHL occurred in a saltatory manner. The risk of developing a new lesion was 50% per year. We found no evidence for VEGF secretion from CNS hemangioblastomas in vHL in circulating blood. Other potential biomarkers should be explored to assess progression of tumor burden in vHL.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0278166","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T18:43:59Z","timestamp":1669661039000},"page":"e0278166","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Central nervous system hemangioblastomas in von Hippel-Lindau disease: Total growth rate and risk of developing new lesions not associated with circulating VEGF levels"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-0508","authenticated-orcid":true,"given":"Jimmy","family":"Sundblom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor Persson","family":"Skare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staffan","family":"Welin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelene","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pelle","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Enblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet Ohlin","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"9374","key":"pone.0278166.ref001","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"RR Lonser","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"pone.0278166.ref002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3171\/jns.2003.98.1.0082","article-title":"The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease","volume":"98","author":"JE Wanebo","year":"2003","journal-title":"J Neurosurg"},{"issue":"3","key":"pone.0278166.ref003","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3174\/ajnr.A5032","article-title":"Genetics of Von Hippel-Lindau Disease","volume":"38","author":"DC Dwyer","year":"2017","journal-title":"AJNR Am J Neuroradiol"},{"key":"pone.0278166.ref004","article-title":"A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease","author":"SK Flores","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0278166.ref005","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1038\/srep12605","article-title":"Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein","volume":"5","author":"G Minervini","year":"2015","journal-title":"Sci Rep"},{"issue":"18","key":"pone.0278166.ref006","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2015.65.6140","article-title":"Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome","volume":"34","author":"SM Nielsen","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0278166.ref007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2350-11-4","article-title":"Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease","volume":"11","author":"A Rasmussen","year":"2010","journal-title":"BMC Med Genet"},{"issue":"1","key":"pone.0278166.ref008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-0004.2009.01281.x","article-title":"Surveillance in von Hippel-Lindau disease (vHL)","volume":"77","author":"ML Poulsen","year":"2010","journal-title":"Clin Genet"},{"issue":"4","key":"pone.0278166.ref009","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","article-title":"Life expectancy in hereditary cancer predisposing diseases: an observational study","volume":"49","author":"A Wilding","year":"2012","journal-title":"J Med Genet"},{"issue":"1","key":"pone.0278166.ref010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3171\/jns.2003.98.1.0095","article-title":"Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease","volume":"98","author":"RJ Weil","year":"2003","journal-title":"J Neurosurg"},{"issue":"1","key":"pone.0278166.ref011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3171\/jns.2003.98.1.0106","article-title":"Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease","volume":"98","author":"RR Lonser","year":"2003","journal-title":"J Neurosurg"},{"issue":"3","key":"pone.0278166.ref012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.15586\/jkcvhl.2017.90","article-title":"Management Strategies and Outcomes for VHL-related Craniospinal Hemangioblastomas","volume":"4","author":"C Ordookhanian","year":"2017","journal-title":"J Kidney Cancer VHL"},{"issue":"4","key":"pone.0278166.ref013","doi-asserted-by":"crossref","first-page":"44368","DOI":"10.2144\/000112551","article-title":"Self-assembly of proximity probes for flexible and modular proximity ligation assays","volume":"43","author":"S Darmanis","year":"2007","journal-title":"Biotechniques"},{"issue":"1","key":"pone.0278166.ref014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/neup.12316","article-title":"Study of angiogenic signaling pathways in hemangioblastoma","volume":"37","author":"D Pierscianek","year":"2017","journal-title":"Neuropathology"},{"issue":"3","key":"pone.0278166.ref015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02484282","article-title":"Clinicopathological study of vascular endothelial growth factor (VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas","volume":"17","author":"M Miyagami","year":"2000","journal-title":"Brain Tumor Pathol"},{"issue":"3","key":"pone.0278166.ref016","first-page":"510","article-title":"Interferon alpha-2a therapy in 18 hemangioblastomas","volume":"7","author":"M Niemel\u00e4","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"12","key":"pone.0278166.ref017","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease","volume":"22","author":"E Jonasch","year":"2011","journal-title":"Ann Oncol"},{"issue":"8","key":"pone.0278166.ref018","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.291.8.943","article-title":"Antiangiogenic therapy for von Hippel-Lindau disease","volume":"291","author":"S Madhusudan","year":"2004","journal-title":"JAMA"},{"key":"pone.0278166.ref019","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1874364101004010066","article-title":"Long-term use of intravitreal bevacizumab (avastin) for the treatment of von hippel-lindau associated retinal hemangioblastomas","volume":"4","author":"FN Hrisomalos","year":"2010","journal-title":"Open Ophthalmol J"},{"issue":"1","key":"pone.0278166.ref020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-0037-1615158","article-title":"Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation","volume":"80","author":"U Wartiovaara","year":"1998","journal-title":"Thromb Haemost"},{"issue":"8","key":"pone.0278166.ref021","doi-asserted-by":"crossref","first-page":"e0220902","DOI":"10.1371\/journal.pone.0220902","article-title":"Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population","volume":"14","author":"V Gorenjak","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"pone.0278166.ref022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1515\/CCLM.2011.049","article-title":"Impact of cryopreservation on serum concentration of matrix metalloproteinases (MMP)-7, TIMP-1, vascular growth factors (VEGF) and VEGF-R2 in Biobank samples","volume":"49","author":"K Kisand","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"pone.0278166.ref023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","volume":"8","author":"S Engelborghs","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"pone.0278166.ref024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1752-0509-5-193","article-title":"Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies","volume":"5","author":"SD Finley","year":"2011","journal-title":"BMC Syst Biol"},{"issue":"5","key":"pone.0278166.ref025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cbt.5.5.2657","article-title":"Proteomic analysis of hemangioblastoma cyst fluid","volume":"5","author":"S Gl\u00e4sker","year":"2006","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"pone.0278166.ref026","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3171\/2014.1.JNS131431","article-title":"Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease","volume":"120","author":"RR Lonser","year":"2014","journal-title":"J Neurosurg"},{"issue":"9","key":"pone.0278166.ref027","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-14-0366","article-title":"TGR analysis in phase I clinical trials\u2014response","volume":"20","author":"C Fert\u00e9","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T18:44:32Z","timestamp":1669661072000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278166"}},"subtitle":[],"editor":[{"given":"Prashant","family":"Chittiboina","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0278166","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}